The clinical diagnosis of Alzheimer’s disease (AD) focuses on the exclusion of other causes of dementia. Because diagnosis of AD can be difficult, there has been considerable interest in identifying an accurate laboratory test for AD, particularly for use early in the course of the disease.
Several cerebrospinal fluid (CSF) peptide markers and urine markers have been investigated as possible predictors of AD and include the following:
Tau protein is a microtubule-associated molecule that is found in the neurofibrillary tangles that are typical of AD. This protein is thought to be related to degenerating and dying neurons.
AAB-42 is a subtype of amyloid beta peptide that is produced following the metabolism of amyloid precursor protein. AB-42 is the key peptide deposited in the amyloid plaques characteristic of AD.
Low levels of AB-42 in the CSF have been associated with AD.
Neural thread protein is associated with the neurofibrillary tangles of AD. Both CSF and urine levels of this protein have been investigated as a potential marker of AD.
ADmark® CSF Analysis tests for phosphorylated tau protein, total tau protein and amyloid-β peptide 1-42 peptide in cerebrospinal fluid. AlzheimAlert™ tests for neural thread protein in urine or cerebrospinal fluid.
Measurement of cerebrospinal fluid biomarkers of Alzheimer’s disease, including, but not limited to tau protein, amyloid beta peptides, or neural thread proteins, is considered investigational.
Measurement of urinary biomarkers of Alzheimer’s disease, including, but not limited to neural thread proteins, is considered investigational.
Any specific products referenced in this policy are just examples and are intended for illustrative purposes only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available. These examples are contained in the parenthetical e.g. statement.
We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.
Evidence for the use of biochemical markers to diagnose Alzheimer’s disease does not demonstrate incremental improvement in diagnostic accuracy over clinical testing.
Alzheimer’s Association. (2019). Earlier diagnosis. Retrieved June 4, 2019 from https://www.alz.org/alzheimers-dementia/research_progress/earlier-diagnosis.
BlueCross BlueShield Association. Evidence Positioning System. (1:2019). Cerebrospinal fluid and urinary biomarkers of Alzheimer disease (2.04.14). Retrieved May 30, 2019 from https://www.evidencepositioningsystem.com/ (48 articles and/or guidelines reviewed)
Herukka, S.K., Simonsen, A.H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., et al. (2017). Recommendations for cerebrospinal fluid Alzheimer’s disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer’s & Dementia, 13, 285-295. (Level 1 evidence)
McKhann, G., Knopman, D., Chertkow, H., Hyman, B., Jack, C., Kawas, C., et al. (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, 7 (3), 263-269. (Level 2 evidence)
National Institutes of Health. National Institute on Aging. (2019). Biomarkers for dementia detection and research. Retrieved June 4, 2019 from https://www.nia.nih.gov/health/biomarkers-dementia-detection-and-research#future.
Olsson, B., Schott, J., Blennow, K., & Zetterberg, H. (2017). The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer’s disease clinical trials. Expert Review of Neurotherapeutics, 2017 Jun 19:1-9. Doi: 10.1080/14737175.2017.1341311. [Epub ahead of print]. Abstract retrieved June 26, 2017 from PubMed database.
Rosa, M.I., Perucchi, J., Medeiros, L.R., Fernandes, B., Fernandes, D., & Silva, B.R. (2014). Accuracy of cerebrospinal fluid (Aβ(1-42) for Alzheimer’s disease diagnosis: a systematic review and meta-analysis. Journal of Alzheimer’s Disease, 40 (2), 443-454. Abstract retrieved June 5, 2018 from PubMed database.
Zhang, J., Zhang, C.H., Li, R.J., Lin, X.L., Chen, Y.D., Gao, H.Q., & Shi, S.L. (2014). Accuracy of urinary AD7c-NTP for diagnosing Alzheimer’s disease: a systematic review and meta-analysis. Journal of Alzheimer’s Disease, 40 (1), 153-159. Abstract retrieved June 5, 2018 from PubMed database.
MOST RECENT REVIEW DATE: 7/11/2019
Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.
This document has been classified as public information.